View Older Stories

Feb 23, 2026 08:17AM ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 5c

Feb 23, 2026 07:01AM ImmunityBio reports 700% revenue growth, expands approvals globally

Feb 20, 2026 08:30AM ImmunityBio partners to launch ANKTIVA cancer drug in Saudi Arabia

Feb 19, 2026 09:02AM ImmunityBio partners with Accord Healthcare for European ANKTIVA launch

Feb 18, 2026 09:01AM ImmunityBio wins European approval for bladder cancer treatment

Feb 17, 2026 06:09AM ImmunityBio discusses drug approvals with Saudi regulators

Jan 26, 2026 06:49AM Immunitybio Inc (IBRX) PT Raised to $10 at H.C. Wainwright

Jan 23, 2026 07:00AM ImmunityBio reports survival data from glioblastoma trial

Jan 22, 2026 01:17PM Immunitybio Inc (IBRX) PT Raised to $9 at BTIG

Jan 21, 2026 10:09AM Increasing unusual call option volume: SAVA GORO IBRX VET XP IGV MRAM RMBS ONON BLDP

Jan 20, 2026 07:44AM Immunitybio Inc (IBRX) PT Raised to $7 at Piper Sandler

Jan 16, 2026 10:44AM Increasing unusual option volume: IRE IBRX QNCX FE IREX RVMD RPD

Jan 16, 2026 07:00AM ImmunityBio reports 15-month response in lymphoma cell therapy trial

Jan 16, 2026 07:00AM ImmunityBio reports progress in bladder cancer trial enrollment

Jan 15, 2026 08:41AM ImmunityBio releases preliminary 2025 financial results

Jan 15, 2026 08:32AM ImmunityBio reports $113 million revenue, 700% annual increase

Jan 14, 2026 08:30AM ImmunityBio gets Saudi approval for bladder cancer treatment ANKTIVA

Jan 13, 2026 08:30AM ImmunityBio reports positive lung cancer trial results for ANKTIVA

Dec 29, 2025 06:04AM ImmunityBio amends stock sale agreement to authorize $460M offering

Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026

Dec 16, 2025 09:01AM ImmunityBio's ANKTIVA shows 96% survival in bladder cancer study

Dec 12, 2025 11:37AM Immunitybio Inc (IBRX) PT Raised to $9 at Jefferies

Dec 12, 2025 06:10AM ImmunityBio gets european drug agency nod for bladder cancer treatment

Nov 5, 2025 01:58AM ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

Sep 10, 2025 07:30AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)

Sep 8, 2025 08:30AM ImmunityBio reports ANKTIVA therapy reverses lymphopenia in lung cancer

Aug 26, 2025 08:31AM ImmunityBio reports early trial results in brain cancer treatment

Aug 13, 2025 08:31AM ImmunityBio reports complete responses in lymphoma trial with CAR-NK therapy

Aug 5, 2025 07:31AM ImmunityBio, Inc. (IBRX) Tops Q2 EPS by 1c

Jul 25, 2025 06:06AM ImmunityBio raises $80 million from institutional investors

Jun 4, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)

Jun 2, 2025 09:02AM ImmunityBio (IBRX) receives FDA Expanded Access for Cancer BioShield platform

May 20, 2025 06:43AM Piper Sandler Upgrades Immunitybio Inc (IBRX) to Overweight, 'ANKTIVA Growing w/ Expansion Opps'

May 13, 2025 04:32PM BTIG Reiterates Buy Rating on Immunitybio Inc (IBRX)

May 12, 2025 06:36AM ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 2c

May 5, 2025 07:51AM ImmunityBio (IBRX) receives Refusal to File letter from FDA for sBLA for use of ANKTIVA plus Bacillus Calmette-Guerin

Apr 29, 2025 07:25AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)

Apr 15, 2025 08:01AM ImmunityBio (IBRX) Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 8, 2025 07:32AM ImmunityBio (IBRX) Announces Execution of $75 Million Equity Financing with an Institutional Investor

Mar 14, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)

Mar 6, 2025 06:03AM H.C. Wainwright Starts Immunitybio Inc (IBRX) at Buy

Mar 3, 2025 04:23PM ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 8c

Feb 28, 2025 09:11AM ImmunityBio (IBRX) Receives FDA RMAT Designation for ANKTIVA and CAR-NK

Feb 19, 2025 09:01AM ImmunityBio (IBRX): FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 13, 2025 03:06PM ImmunityBio (IBRX) Announces UK MHRA Accepted MAA for ANKTIVA for Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma

Jan 29, 2025 08:39AM ImmunityBio (IBRX) Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 16, 2025 03:03PM ImmunityBio (IBRX) Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency (earlier)

Jan 10, 2025 06:06AM BTIG Starts Immunitybio Inc (IBRX) at Buy

Jan 6, 2025 09:03AM ImmunityBio (IBRX) Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Dec 11, 2024 07:31AM ImmunityBio (IBRX) Prices 33.33M Sharee Offering at $3/sh

View Older Stories